RESUMEN

OBJECTIVE: To compare the effects of transurethral resection of the prostate (TURP) and transurethral columnar balloon dilatation of the prostate (TUCBDP) in the treatment of BPH. METHODS: This study included 218 BPH patients treated in Qinhuangdao Workers' Hospital from July 2021 to November 2022, 109 by TURP and the other 109 by TUCBDP. We followed up the patients for 12 months, observed their postoperative recovery, complications, serum pain, inflammatory index, cytokine level, urodynamic index, symptom improvement and quality of life (QOL) and compared the data obtained between the two groups of patients. RESULTS: At 12 months after surgery, the total effectiveness rate was significantly higher in the TUCBDP than in the TURP group (93.58% vs 84.40%, P< 0.05), and the postoperative recovery was better in the former than in the latter (P< 0.05). Compared with the baseline, the levels of serum prostaglandin E2 (PGE2), substance P, tumor necrosis factor-alpha (TNF-α) and high sensitive C-reactive protein (hs-CRP) were remarkably increased in both of the groups on the first day after surgery (P< 0.05), more significantly in the TURP than in the TUCBDP group (P< 0.05), while the levels of serum PSA and E2 decreased and the T level elevated in all the patients at 3 months postoperatively (P< 0.05), more significantly in the TUCBDP than in the TURP group (P< 0.05). Before and at 3 and 12 months after operation, the postvoid residual urine volume (PVR) and NIH-CPSI, IPSS and QOL scores showed a decreasing trend, while the maximum urinary flow rate (Qmax), maximum cystometric capacity (MCC) and maximum urethral closure pressure (MUCP) exhibited an increasing trend in both of the two groups, even more significantly in the TUCBDP than in the TURP group (P< 0.05). CONCLUSION: TUCBDP is advantageous over TURP in promoting postoperative recovery, improving QOL, reducing postoperative pain, inflammation and complications, regulating the levels of serum cytokines, and improving urodynamics and clinical symptoms in BPH patients. However, with the extension of postoperative time, the two strategies are basically comparable in improving the urodynamics, symptoms and QOL of the patients.

Asunto(s)

Hiperplasia Prostática , Calidad de Vida , Resección Transuretral de la Próstata , Humanos , Masculino , Hiperplasia Prostática/cirugía , Resección Transuretral de la Próstata/métodos , Dilatación/métodos , Resultado del Tratamiento , Próstata/cirugía , Proteína C-Reactiva/análisis , Anciano , Dinoprostona/sangre , Persona de Mediana Edad , Factor de Necrosis Tumoral alfa/sangre

RESUMEN

Spinal cord injury (SCI) is one of the most destructive diseases. The neuroinflammation microenvironment needs comprehensive mitigation of damages. Thus, regulation of local, microenvironment drugs could be a potential effective treatment. However, clinical studies on SCI with common treatment have reported it to cause systemic toxicity and side effects. Zinc oxide nanoparticles (ZnONPs) have been widely reported to have satisfying anti-inflammation function. Furthermore, green synthesis procedures can improve the capability and possible utilization of ZnONPs. However, the efficient administration and underlying mechanism of ZnONPs in SCI treatment remain unclear. Herein, an innovative approach was built by utilizing ZnONPs loaded in a skeletal muscle-derived adhesive hydrogel (ZnONPs-Gel). Different from the systemic application of ZnONPs, the local administration of ZnONPs-Gel offered the ZnONPs-loaded extracellular matrix with beneficial biocompatibility to the injured spinal cord, thereby promoting effective function recovery. Mechanistically, the ZnONPs-Gel treatment not only markedly reduced ROS production but also decreased apoptosis in the injured spinal cord. Therefore, the strategy based on local administration of the ZnONPs-Gel in the early stage of SCI may be an effective therapeutic treatment.

RESUMEN

Two new inorganic-organic coordination polymers, namely poly[[µ6-2-(4-{1-[4-(carboxymethoxy)phenyl]-1-methylethyl}phenoxy)acetato][µ4-2-(4-{1-[4-(carboxymethoxy)phenyl]-1-methylethyl}phenoxy)acetato]disodium(I)], [Na2(C19H19O6)2]n, (I), and poly[hexa-µ-aqua-diaquabis{µ3-2,2'-[sulfonylbis(1,4-phenyleneoxy)]diacetato}tetrasodium(I)], [Na4(C16H14O8)2(H2O)8]n, (II), have been prepared. In (I), the asymmetric unit contains two Na(I) cations and two 2-(4-{1-[4-(carboxymethoxy)phenyl]-1-methylethyl}phenoxy)acetate (HL1(-)) ligands. Each Na(I) cation is octahedrally coordinated by two ether O atoms and four carboxylate O atoms of three different HL1(-) ligands. The NaO6 polyhedra share edges to form an inorganic ribbon along the a axis. These inorganic ribbons are further connected by the HL1(-) ligands to generate two-dimensional layers parallel to the (001) plane. The structure of (II) consists of ribbons of four crystallographically independent Na atoms (three six- and one five-coordinate), which are bridged by carboxylate O atoms of 4,4'-[sulfonylbis(1,4-phenyleneoxy)]diacetate (L2(2-)) ligands and water molecules. These ribbons are interlinked by L2(2-) ligands through two different coordination modes to afford a three-dimensional network.